Improving outcomes in patients undergoing percutaneous coronary intervention: role of prasugrel

References

• NeumannFJGawazMOttIMayAMössmerGSchömigAProspective evaluation of hemostatic predictors of subacute stent thrombosis after coronary Palmaz-Schatz stentingJ Am Coll Cardiol19962715218522689
   PubMed Web of Science ®Google Scholar
• MakkarRREiglerSKaulSEffects of clopidogrel, aspirin and combined therapy in a porcine ex vivo model of high-shear induced stent thrombosisEur Heart J199819153815469820993
   PubMed Web of Science ®Google Scholar
• LenzenMJBoersmaEBertrandMEEuropean Society of CardiologyManagement and outcome of patients with established coronary artery disease: the Euro Heart Survey on coronary revascularizationEur Heart J200526121169117915802360
   PubMed Web of Science ®Google Scholar
• ThomTHaaseNRosamondWAmerican Heart Association Statistics Committee and Stroke Statistics SubcommitteeHeart disease and stroke statistics – 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics SubcommitteeCirculation20061136e85e10116407573
   PubMed Web of Science ®Google Scholar
• SaviPPereilloJMUzabiagaMFIdentification and biological activity of the active metabolite of clopidogrelThromb Haemost20008489189611127873
   PubMed Web of Science ®Google Scholar
• IbanezBVilahurGBadimonJJPharmacology of thienopyridines: rationale for dual pathway inhibitionEur Heart J Suppl20068G3G9
   Web of Science ®Google Scholar
• BertrandMERupprechtHJUrbanPGershlickAHDouble-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS)Circulation200010262462910931801
   PubMed Web of Science ®Google Scholar
• BhattDLBertrandMEBergerPBMeta-analysis of randomized and registry comparisons of ticlopidine and clopidogrel after stentingJ Am Coll Cardiol20023991411755280
   PubMed Web of Science ®Google Scholar
• SilberSAlbertssonPAvilesFFfor Task Force for Percutaneous Coronary Interventions of the European Society of CardiologyGuidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of CardiologyEur Heart J200526880484715769784
   PubMed Web of Science ®Google Scholar
• EshaghianSKaulSAminSShahPKDiamondGARole of clopido-grel in managing atherothrombotic cardiovascular diseaseAnn Intern Med2007146643444117371888
   PubMed Web of Science ®Google Scholar
• QuinnMJBhattDLZidarFEffect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary interventionAm J Cardiol20049367968415019868
   PubMed Web of Science ®Google Scholar
• VivekananthanDPBhattDLChewDPEffect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary interventionAm J Cardiol20049435836015276105
   PubMed Web of Science ®Google Scholar
• PereilloJMMaftouhMAndrieuAStructure and stereochemistry of the active metabolite of clopidogrelDrug Metab Dispos2002301288129512386137
   PubMed Web of Science ®Google Scholar
• ClarkeTAWaskellLAThe metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatinDrug Metab Dispos200331535912485953
   PubMed Web of Science ®Google Scholar
• GurbelPABlidenKPHiattBLO’ConnorCMClopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivityCirculation20031072908291312796140
   PubMed Web of Science ®Google Scholar
• SerebruanyVLSteinhublSRBergerPBMalininAIBhattDLTopolEJVariability in platelet responsiveness to clopidogrel among 544 individualsJ Am Coll Cardiol20054524625115653023
   PubMed Web of Science ®Google Scholar
• WallentinLVarenhorstCJamesSPrasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery diseaseEur Heart J200829213018055486
   PubMed Web of Science ®Google Scholar
• TaubertDvon BeckerathNGrimbergGImpact of P-glycoprotein on clopidogrel absorptionClin Pharmacol Ther20068048650117112805
   PubMed Web of Science ®Google Scholar
• SimonTVerstuyftCMary-KrauseMGenetic determinants of response to clopidogrel and cardiovascular eventsN Engl J Med200936036337519106083
   PubMed Web of Science ®Google Scholar
• MotovskaZWidimskyPPetrRon behalf of the PRAGUE-8 Study InvestigatorsFactors influencing clopidogrel efficacy in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention: statin’s advantage and the smoking “paradox”J Cardiovasc Pharmacol2009225[Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• MotovskaZWidimskyPPetrROptimal pretreatment timing for high load dosing (600 mg) of clopidogrel before planned percutaneous coronary intervention for maximal antiplatelet effectivenessInt J Cardiol2009214[Epub ahead of print]
   PubMedGoogle Scholar
• DavìGGreselePVioliFDiabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial diseaseCirculation199796169759236419
   PubMed Web of Science ®Google Scholar
• SofferDMoussaIHarjaiKImpact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: do we need more aggressive dosing regimens in unstable anginaCatheter Cardiovasc Interv200359212512720236
   PubMed Web of Science ®Google Scholar
• MontalescotGSiderisGMeulemanCfor the ALBION Trial InvestigatorsA randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trialJ Am Coll Cardiol20064893193816949482
   PubMed Web of Science ®Google Scholar
• GeislerTLangerHWydymusMLow response to clopidogrel is associated with cardiovascular outcome after coronary stent implantationEur Heart J200627202420242517005534
   PubMed Web of Science ®Google Scholar
• AngiolilloDJBernardoESabateMImpact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery diseaseJ Am Coll Cardiol2007501541154717936152
   PubMed Web of Science ®Google Scholar
• von BeckerathNTaubertDPogatsa-MurrayGSchomigEKastratiASchomigAAbsorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: Results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) TrialCirculation2005112192946295016260639
   PubMed Web of Science ®Google Scholar
• BuonamiciPMarcucciRMiglioriniAImpact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosisJ Am Coll Cardiol200749242312231717572245
   PubMed Web of Science ®Google Scholar
• FaridNASmithRLGillespieTAThe disposition of prasugrel, a novel thienopyridine, in humansDrug Metab Dispos2007351096110417403916
   PubMed Web of Science ®Google Scholar
• JakubowskiJAWintersKJNaganumaHWallentinLPrasugrel: A novel thienopyridine antiplatelet agentCardiovasc Drug Rev200725435737418078435
   PubMed Web of Science ®Google Scholar
• BrandtJTPayneCDWiviottSDA comparison of prasugrel and clopidogrel loading doses on platelet function: Magnitude of platelet inhibition is related to active metabolite formationAm Heart J2007153e9e1617174640
   PubMed Web of Science ®Google Scholar
• WiviottSDTrenkDFrelingerALPrasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trialCirculation20071162923293218056526
   PubMed Web of Science ®Google Scholar
• SugidachiAOgawaTKuriharaAThe greater in vivo anti-platelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel’s active metaboliteJ Thromb Haemost200751545155117456192
   PubMed Web of Science ®Google Scholar
• MullerIBestaFSchulzCMassbergSSchomigAGawazMPrevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placementThromb Haemost20038978378712719773
   PubMed Web of Science ®Google Scholar
• LevEIPatelRTMareshKJAspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistanceJ Am Coll Cardiol2006471273316386660
   PubMed Web of Science ®Google Scholar
• MatetzkySShenkmanBGuettaVClopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarctionCirculation20041093171317515184279
   PubMed Web of Science ®Google Scholar
• JernbergTPayneCDWintersKJPrasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery diseaseEur Heart J2006271166117316621870
   PubMed Web of Science ®Google Scholar
• MotovskaZKalaPBenefits and risks of clopidogrel use in patients with coronary artery disease: Evidence from randomized studies and registriesClin Ther200830P22191220219281914
   PubMedGoogle Scholar
• WiviottSDBraunwaldEMcCabeCHTRITON-TIMI 38 InvestigatorsPrasugrel versus clopidogrel in patients with acute coronary syndromesN Eng J Med200735720012015
   PubMed Web of Science ®Google Scholar
• MontalescotGWiviottSDBraunwaldEMurphySAGibsonCMMcCabeCHAntmanEMTRITON-TIMI 38 investigatorsPrasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trialLancet2009373966572373119249633
   PubMed Web of Science ®Google Scholar
• US National Institutes of Health. A comparison of prasugrel and clopi-dogrel in acute coronary syndrome subjects (TRILOGY ACS). April 20, 2009. Accessed on May 6, 2009. Available from: http://clinicaltrials.gov/ct2/show/NCT00699998
   Google Scholar
• WenaweserPReyCEberliFStent thrombosis following bare-metal stent implantation success of emergency percutaneous coronary intervention and predictors of adverse outcomeEur Heart J200526121180118715728650
   PubMed Web of Science ®Google Scholar
• CookSWindeckerSEarly stent thrombosis: Past, present, and futureCirculation200911965765919204315
   PubMed Web of Science ®Google Scholar
• IakovouISchmidtTBonizzoniEIncidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stentsJAMA20052932126213015870416
   PubMed Web of Science ®Google Scholar
• WiviottSDBraunwaldEMcCabeCHIntensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a sub-analysis of a randomised trialLancet200837196211353136318377975
   PubMed Web of Science ®Google Scholar
• WiviottSDBraunwaldEAngiolilloDJTRITON-TIMI 38 InvestigatorsGreater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel - Thrombolysis in Myocardial Infarction 38Circulation2008118161626163618757948
   PubMed Web of Science ®Google Scholar
• DonahoeSMStewartGCMcCabeCHDiabetes and mortality following acute coronary syndromesJAMA200729876577517699010
   PubMed Web of Science ®Google Scholar
• YusufSZhaoFMehtaSRChrolaviciusSTognoniGFoxKKEffects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevationN Engl J Med200134549450211519503
   PubMed Web of Science ®Google Scholar
• AngiolilloDJShowmakerSBDesaiBRandomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the optimizing anti-platelet therapy in diabetes mellitus (OPTIMUS) studyCirculation2007115670871617261652
   PubMed Web of Science ®Google Scholar
• AngiolilloDJBernardoESabateMImpact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery diseaseJ Am Coll Cardiol2007501541154717936152
   PubMed Web of Science ®Google Scholar
• ErlingeDVarenhorstCBraunOÖPatients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivoJ Am Coll Cardiol2008521968197719055987
   PubMed Web of Science ®Google Scholar
• WiviottSDBraunwaldEAngiolilloDJGreater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in TRITON-TIMI 38Circulation20081181626163618757948
   PubMed Web of Science ®Google Scholar
• MotovskaZWidimskyPKvasnickaJon behalf of the PRAGUE-8 study investigatorsHigh loading dose of clopidogrel is unable to satisfactorily inhibit platelet reactivity in patients with glycoprotein IIIA gene polymorphism – a genetic substudy of PRAGUE-8 trialBlood Coagul Fibrin2009316doi:10.1097/MBC.0b013e328325455b.
   PubMed Web of Science ®Google Scholar
• SimonTVerstuyftCMary-KrauseMGenetic determinants of response to clopidogrel and cardiovascular eventsN Engl J Med200936036337519106083
   PubMed Web of Science ®Google Scholar
• MegaJLCloseSLWiviottSDCytochrome P-450 polymorphisms and response to clopidogrelN Engl J Med200936035436219106084
   PubMed Web of Science ®Google Scholar
• BrandtJTCloseSLIturriaSJCommon polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacody-namic response to clopidogrel but not prasugrelJ Thromb Haemost200752429243617900275
   PubMed Web of Science ®Google Scholar
• Eli Lilly and CompanyEuropean Commission approves EFIENT (prasugrel) for patients with acute coronary syndrome undergoing PCI [press release]. February 23, 2009. Accessed on May 6, 2009. Available from: http://newsroom.lilly.com/releasedetail.cfm?ReleaseID=366955
   Google Scholar
• Eli Lilly and CompanyPrasugrel receives unanimous approval recommendation from FDA Advisory Committee. February 3, 3009. Accessed on May 6, 2009. Available from: http://www.drugs.com/nda/effient_090204.html
   Google Scholar